ClinicalTrials.gg

Program

Niclosamide

Also written as “Niclosamide Oral Tablet”, “CP-PCA07” and “Niclosamide Inhalation Powder”.

Its studies are mostly in COVID-19 · Prostatic Neoplasms · Colitis, Ulcerative, led by 6 companies.

Furthest: phase 3, since Apr 17, 201810 company-led studies, 1 open or runningNext primary completion: Sep 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Entero Therapeutics40 open or runningphase 2since Apr 17, 2018Apr 17, 2018none ahead
NeuroBo Pharmaceuticals20 open or runningphase 3since Oct 20, 2020Oct 20, 2020none ahead
Hyundai Bioscience11 open or runningphase 1since Jun 23, 2026Jun 23, 2026Sep 2027phase 1 · NCT07683013
Imuneks Farma ilac San. Tic. A.S.10 open or runningphase 3since Sep 18, 2020Sep 18, 2020none ahead
TFF Pharmaceuticals10 open or runningphase 1since Dec 20, 2021Dec 20, 2021none ahead
UNION therapeutics10 open or runningphase 2since Jun 18, 2021Jun 18, 2021none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 17, 2018First study: phase 2 study in Colitis, UlcerativeNew to Entero TherapeuticsEntero Therapeutics · NCT03521232 · 27 enrolled · Italy
  2. Jun 16, 2020Phase 2 study in COVIDEntero Therapeutics · NCT04436458
  3. Sep 4, 2020Phase 2 study in COVID-19Entero Therapeutics · NCT04542434
  4. Sep 18, 2020Imuneks Farma ilac San. Tic. A.S.'s first study: phase 3 study in COVID-19New to Imuneks Farma ilac San. Tic. A.S.Imuneks Farma ilac San. Tic. A.S. · NCT04558021 · 200 enrolled · Turkey
  5. Oct 20, 2020NeuroBo Pharmaceuticals's first study: phase 3 study in COVID-19New to NeuroBo PharmaceuticalsNeuroBo Pharmaceuticals · NCT04603924 · 49 enrolled · United States
  6. Dec 8, 2020Phase 1 study in HealthyNeuroBo Pharmaceuticals · NCT04705415 · 54 enrolled · United States
  7. Apr 21, 2021Phase 2 study in COVID-19Entero Therapeutics · NCT04858425 · 166 enrolled · United States, India, Ukraine
  8. Jun 18, 2021UNION therapeutics's first study: phase 2 study in COVID-19New to UNION therapeuticsUNION therapeutics · NCT04932915 · 4 enrolled · Germany
  9. Dec 20, 2021TFF Pharmaceuticals's first study: phase 1 study in HealthyNew to TFF PharmaceuticalsTFF Pharmaceuticals · NCT05168644 · 40 enrolled · Canada
  10. Jun 23, 2026Hyundai Bioscience's first study: phase 1 study in Castration-Resistant Prostate Cancer (CRPC)New to Hyundai BioscienceHyundai Bioscience · NCT07683013 · 18 planned · South Korea

Ahead

  1. Sep 2027Primary completion: phase 1 study in Castration-Resistant Prostate Cancer (CRPC)Hyundai Bioscience · NCT07683013

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“DNA inhibitor; DNA inhibitor”ChEMBL 37, by rule

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07683013Castration-Resistant Prostate Cancer (CRPC) · South Korea1Not yet recruitingHyundai BioscienceSep 202718
NCT05168644Healthy · Canada1CompletedTFF PharmaceuticalsJan 26, 202240
NCT04932915COVID-19 · Germany2TerminatedUNION therapeuticsJan 10, 20224
NCT04858425COVID-19 · United States, India, Ukraine2TerminatedEntero TherapeuticsJun 4, 2022166
NCT04705415Healthy · United States1CompletedNeuroBo PharmaceuticalsOct 13, 202154
NCT04603924COVID-19 · United States3CompletedNeuroBo PharmaceuticalsFeb 16, 202249
NCT04558021COVID-19 · Turkey3UNKNOWNImuneks Farma ilac San. Tic. A.S.Jan 30, 2021200
NCT04542434COVID-192WithdrawnEntero TherapeuticsJan 20, 20220
NCT04436458COVID2WithdrawnEntero TherapeuticsJan 20, 20220
NCT03521232Colitis, Ulcerative · Italy2TerminatedEntero TherapeuticsSep 19, 202227

How it is read

Names in the registry

  • “Niclosamide”, 5 entries
  • “Niclosamide Oral Tablet”, 2 entries
  • “CP-PCA07”, 1 entry
  • “Niclosamide Inhalation Powder”, 1 entry
  • “Niclosamide suspension”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.